Nkarta (NKTX) announced the appointment of Shawn Rose as its next Chief Medical Officer and Head of Research and Development starting on June 23. He replaces David Shook, who will be stepping down from the role to pursue other opportunities in the oncology space. Rose most recently served as Chief Development Officer, Immunology, at Vividion Therapeutics, working to expand their portfolio by advancing previously undruggable targets in immunology.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTX: